RecruitingNot ApplicableNCT07243639

Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis

A Prospective Study on the Efficacy and Safety of a Novel Oral Drug, Etrasimod, in Elderly Patients With Ulcerative Colitis

Sponsor

Showa Inan General Hospital

Enrollment

30 participants

Start Date

Oct 1, 2025

Study Type

INTERVENTIONAL

Conditions

Ulcerative Colitis (Disorder)

Summary

Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is testing the effectiveness and safety of etrasimod — a drug that helps control immune system overactivity — in elderly patients with active ulcerative colitis, an inflammatory bowel disease that causes chronic inflammation and ulcers in the large intestine. **You may be eligible if...** - You are an elderly patient with active ulcerative colitis - You have not achieved adequate disease control with current treatments **You may NOT be eligible if...** - You have acute or chronic kidney failure - You have chronic heart disease - You have a pulmonary (lung) infection - You have liver cirrhosis - You have colorectal cancer - You have an autoimmune disease other than ulcerative colitis - You have an active infectious disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.